No Photo Available

Last Update

2017-02-16T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Andrew Griffiths?

Prof. Andrew Griffiths

Scientific Founder

HiFiBiO

HQ Phone: (617) 863-3679

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

HiFiBiO

700 Main St

Cambridge, Massachusetts 02139

United States

Company Description

HiFiBiO's platform employs paired bar coding, next generation sequencing and rapid DNA synthesis coupled to high throughput cloning and expression enabling single cell-based screening of entire antibody-secreting B cell populations . Identification of div ... more

Find other employees at this company (18)

Background Information

Employment History

Director of the Laboratory of Biological Chemistry At the Institut De Science Et d'Ingénierie Supramoléculaires

Université Louis Pasteur

Director

Louis Pasteur University - France

Expert In Droplet Biochemistry

Medical Research Council

Affiliations

Founder
RainDance Technologies Inc

Scientific Advisory Board Member
Plasticell Ltd

Education

Ph.D.

PhD

Molecular Biology

University of Leicester

Web References (30 Total References)


HiFiBiO: High Fidelity Biology | Your Partners In Antibody Biodiscovery

hifibio.com [cached]

Prof. Andrew Griffiths

Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris.
more
Prof Griffiths is formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg. After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge where he co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995).
This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications. Andrew is a founder of RainDance Technologies.


HiFiBiO

www.hifibio.com [cached]

Prof. Andrew Griffiths

...
Andrew Griffiths is a Professor of Biochemistry at Ecole Superieure de Physique et Chimie Industrielle de Paris (ESPCI) in Paris and formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg. After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge where he co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995). This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications. Andrew is a founder of RainDance Technologies.


Scientific Founders | HiFiBiO: High Fidelity Biology

hifibio.com [cached]

Prof. Andrew Griffiths

...
Andrew Griffiths
...
Andrew Griffiths
Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris and formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg.
After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge where he co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995).
This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications. Andrew is a founder of RainDance Technologies.


Plasticell – Scientific Advisory Board

www.plasticell.co.uk [cached]

Prof Andrew Griffiths

Professor Griffiths is Director of the Laboratory of Biological Chemistry at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS), Université Louis Pasteur, Strasbourg, France. He is a leading expert in combinatorial biology methods, being an inventor on over 19 MRC patents on antibody phage display, and the co-inventor of the in vitro compartmentalization (IVC) method of directed protein evolution on which he currently works. Professor Griffiths was previously a group leader at the MRC Laboratory of Molecular Biology, Cambridge, and holds a PhD in Molecular Biology from the University of Leicester.


Team | BioMillenia

www.biomillenia.com [cached]

Prof. Andrew Griffiths

Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris and formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg. After gaining a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge. While there, he co-developed phage display for the selection of human antibodies for therapy, first as a Post-Doctoral Research Fellow (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995). This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes and high-throughput screening for drug discovery and diagnostic applications. Andrew is a founder of RainDance Technologies.

Similar Profiles

Other People with this Name

Other people with the name Griffiths

Manjeet Griffiths
CIM Online Ltd

David Griffiths
Hyland Software Inc

Robert Griffiths
General Dynamics C4 Systems Inc

Andy Griffiths
CEVA Group Plc

Ben Griffiths
Universitas 21

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory